Insights From the Experts at Teiko

Each antibody on Teiko’s cytometry panels goes through a multi-step verification process to ensure that the selected concentration gives the optimal marker detection without spilling into neighboring channels.

Teiko saves your scientists time and effort by streamlining data processing and analysis, ensuring organized and reliable results. Our advantage is we knit all the pieces together: specimen collection, tracking, panels, report validation, and data delivery. In data delivery, we provide an analytical pipeline that transforms complex cytometry data into actionable insights.

“I have a 13 marker panel that analyzes T-cells. And my drug just hit the T-cells, why bother looking at any other immune cell types, like B cells, or NK cells? Even if those other cells are affected, I don’t know how to interpret those results.”

The reason is: those extra subsets might predict the difference between success and failure for a drug.

The answer to this common question is more complex than you’d think. We use real-world examples to break down how reliability depends on the confidence you need, the variability you can accept, and of course the frequency of the population you’re interested in measuring.

How are our mass cytometry antibodies validated? We discuss how we pair the best of software design with expert scientist intuition to select the best clone, concentration, and cellular condition for each antibody on our panel.

We highlight six recent key discoveries made using mass cytometry across a wide range of blood cancers including AML ALL, lymphoma, and myeloma.

Matthew Spitzer, Associate Professor at UCSF and scientific cofounder of Teiko Bio, explains how understanding each patient’s individual “immune setpoint” could be the key to maximizing cancer treatment efficacy.

What the Costco hotdog and soda deal and inflation can teach us about better understanding the immune system.

Dr. Shernan Holtan discusses her research into a pregnancy hormone that may hold the key to treating life-threatening graft-vs-host diseases and how Teiko helped her overcome the barriers to high-dimensional immune profiling.

Researchers have used scRNAseq and CyTOF as complementary tools in a wide variety of published studies to provide additional breadth, depth, and coverage when analyzing cellular processes. Here are a few specific examples that illustrate the diversity and range of these approaches in a variety of biomedical research settings.

Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline.

What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development.

Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner.